CMP-001 for Relapsed and Refractory Lymphoma

Part of paid clinical trials in Iowa City, Iowa.

Sponsor
Umar Farooq
Study ID
NCT03983668
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CMP-001 — DRUG
    Immunostimulatory therapeutic agent
  • Pembrolizumab — DRUG
    Humanized antibody used in cancer immunotherapy

Study Details

This study is a single-arm, open-label, phase I/II trial designed to find a CMP-001 dose that, in combination with pembrolizumab, has optimal clinical efficacy and acceptable toxicity for patients with relapsed and refractory lymphomas.

Key Dates

Start date
Jan 31, 2020
Status verified
Sep 2025
Primary completion
Aug 23, 2024
Completion
Apr 8, 2025

Study Design

Enrollment
14 participants (actual)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: CMP-001 plus pembrolizumab: Phase I, 5mg dose cohort
    Intratumoral administration of CMP-001 and intravenous administration of pembrolizumab

Primary Outcome Measure

Number of Participants With Dose Limiting Toxicities Using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [ Time Frame: From the start of treatment up to two years ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Iowa Hospitals and ClinicsIowa CityIowa52242-

Related coverage on Hipa.ai

Find similar trials in Iowa City, IA

By research site
University of Iowa Hospitals and Clinics· Iowa City, IA

Related Studies